Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: OVARIAN CANCER, . Treffer: 127

2020

Bizzarri, N; Razumova, Z; Selcuk, I; Taumberger, N; Nikolova, T; Fotopoulou, C; Van der Steen-Banasik, E; Ferrero, A; Zalewski, K Report from the 21st meeting of the European Society of Gynaecological Oncology (ESGO 2019).
Int J Gynecol Cancer. 2020; 30(4):441-447
Web of Science PubMed FullText FullText_MUG

 

Sobočan, M; Bračič, S; Knez, J; Takač, I; Haybaeck, J The Communication Between the PI3K/AKT/mTOR Pathway and Y-box Binding Protein-1 in Gynecological Cancer.
Cancers (Basel). 2020; 12(1): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Tomasch, G; Lemmerer, M; Oswald, S; Uranitsch, S; Schauer, C; Schütz, AM; Bliem, B; Berger, A; Lang, PFJ; Rosanelli, G; Ronaghi, F; Tschmelitsch, J; Lax, SF; Uranues, S; Tamussino, K Prophylactic salpingectomy for prevention of ovarian cancer at the time of elective laparoscopic cholecystectomy.
Br J Surg. 2020; 107(5):519-524 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2019

Lorusso, D; Hilpert, F; González Martin, A; Rau, J; Ottevanger, P; Greimel, E; Lück, HJ; Selle, F; Colombo, N; Kroep, JR; Mirza, MR; Berger, R; Pardo, B; Grischke, EM; Berton-Rigaud, D; Martinez-Garcia, J; Vergote, I; Redondo, A; Cardona, A; Bastière-Truchot, L; du Bois, A; Kurzeder, C; PENELOPE trial investigators Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
INT J GYNECOL CANCER. 2019; 29(7): 1141-1147.
Web of Science PubMed FullText FullText_MUG

 

Wieser, V; Sprung, S; Tsibulak, I; Haybaeck, J; Hackl, H; Fiegl, H; Marth, C; Zeimet, AG Clinical Impact of RANK Signalling in Ovarian Cancer.
Cancers (Basel). 2019; 11(6): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2018

Altman, D; Rogers, RG; Yin, L; Tamussino, K; Ye, W; Iglesia, CB Cancer Risk After Midurethral Sling Surgery Using Polypropylene Mesh.
Obstet Gynecol. 2018; 131(3):469-474
Web of Science PubMed FullText FullText_MUG

 

Dueckelmann, AM; Fink, D; Harter, P; Heinzelmann, V; Marth, C; Mueller, M; Reinthaller, A; Tamussino, K; Wimberger, P; Sehouli, J The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
Arch Gynecol Obstet. 2018; 297(4):837-846
Web of Science PubMed FullText FullText_MUG

 

Friedlander, M; Rau, J; Lee, CK; Meier, W; Lesoin, A; Kim, JW; Poveda, A; Buck, M; Scambia, G; Shimada, M; Hilpert, F; King, MT; Debruyne, P; Bologna, A; Malander, S; Monk, BJ; Petru, E; Calvert, P; Herzog, TJ; Barrett, C; du Bois, A Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
ANN ONCOL. 2018; 29(3): 737-743. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kozar, N; Kruusmaa, K; Bitenc, M; Argamasilla, R; Adsuar, A; Goswami, N; Arko, D; Takač, I Data on metabolomic profiling of ovarian cancer patients' serum for potential diagnostic biomarkers.
Data Brief. 2018; 18: 1825-1831. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Kozar, N; Kruusmaa, K; Bitenc, M; Argamasilla, R; Adsuar, A; Goswami, N; Arko, D; Takač, I Metabolomic profiling suggests long chain ceramides and sphingomyelins as a possible diagnostic biomarker of epithelial ovarian cancer.
Clin Chim Acta. 2018; 481: 108-114.
Web of Science PubMed FullText FullText_MUG

 

Ntoumanoglou-Schuiki, A; Tomasch, G; Laky, R; Taumberger, N; Bjelic-Radisic, V; Tamussino, K Opportunistic prophylactic salpingectomy for prevention of ovarian cancer: What do national societies advise?
EUR J OBSTET GYN R B. 2018; 225(27): 110-112.
Web of Science PubMed FullText FullText_MUG

 

Petru, E; Huber, C; Sampl, E; Haas, J Comparison of Primary Tumor Size in Stage I and III Epithelial Ovarian Cancer.
Anticancer Res. 2018; 38(11):6507-6511
Web of Science PubMed FullText FullText_MUG

 

Qiu, X; Xu, JY; Guo, JJ; Yahia-Ammar, A; Kapetanakis, NI; Duroux-Richard, I; Unterluggauer, JJ; Golob-Schwarzl, N; Regeard, C; Uzan, C; Gouy, S; Dubow, M; Haybaeck, J; Apparailly, F; Busson, P; Hildebrandt, N Advanced microRNA-based cancer diagnostics using amplified time-gated FRET
CHEM SCI. 2018; 9(42): 8046-8055. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Tsibulak, I; Wieser, V; Degasper, C; Shivalingaiah, G; Wenzel, S; Sprung, S; Lax, SF; Marth, C; Fiegl, H; Zeimet, AG BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Br J Cancer. 2018; 119(6):683-692 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Langner, C [Hereditary gastric and pancreatic cancer].
Pathologe. 2017; 38(3):164-169 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Rashed, MH; Kanlikilicer, P; Rodriguez-Aguayo, C; Pichler, M; Bayraktar, R; Bayraktar, E; Ivan, C; Filant, J; Silva, A; Aslan, B; Denizli, M; Mitra, R; Ozpolat, B; Calin, GA; Sood, AK; Abd-Ellah, MF; Helal, GK; Berestein, GL Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.
Oncotarget. 2017; 8(12):20145-20164 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Zeimet, AG; Mori, H; Petru, E; Polterauer, S; Reinthaller, A; Schauer, C; Scholl-Firon, T; Singer, C; Wimmer, K; Zschocke, J; Marth, C AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS).
ARCH GYNECOL OBSTET. 2017; 296(1): 123-127. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2016

Endris, V; Stenzinger, A; Pfarr, N; Penzel, R; Möbs, M; Lenze, D; Darb-Esfahani, S; Hummel, M; Sabine-Merkelbach-Bruse, M; Jung, A; Lehmann, U; Kreipe, H; Kirchner, T; Büttner, R; Jochum, W; Höfler, G; Dietel, M; Weichert, W; Schirmacher, P NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
Virchows Arch. 2016; 468(6):697-705
Web of Science PubMed FullText FullText_MUG

 

Kanlikilicer, P; Rashed, MH; Bayraktar, R; Mitra, R; Ivan, C; Aslan, B; Zhang, X; Filant, J; Silva, AM; Rodriguez-Aguayo, C; Bayraktar, E; Pichler, M; Ozpolat, B; Calin, GA; Sood, AK; Lopez-Berestein, G Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
Cancer Res. 2016; 76(24):7194-7207 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Potz, FL; Tomasch, G; Polterauer, S; Laky, R; Marth, C; Tamussino, K Incidental (Prophylactic) Salpingectomy at Benign Gynecologic Surgery and Cesarean Section: a Survey of Practice in Austria.
Geburtshilfe Frauenheilkd. 2016; 76(12):1325-1329 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Sehouli, J; Chekerov, R; Reinthaller, A; Richter, R; Gonzalez-Martin, A; Harter, P; Woopen, H; Petru, E; Hanker, LC; Keil, E; Wimberger, P; Klare, P; Kurzeder, C; Hilpert, F; Belau, AK; Zeimet, A; Bover-Barcelo, I; Canzler, U; Mahner, S; Meier, W Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Ann Oncol. 2016; 27(12):2236-2241 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Zikos, E; Coens, C; Quinten, C; Ediebah, DE; Martinelli, F; Ghislain, I; King, MT; Gotay, C; Ringash, J; Velikova, G; Reeve, BB; Greimel, E; Cleeland, CS; Flechtner, H; Taphoorn, MJ; Weis, J; Schmucker-von Koch, J; Sprangers, MA; Bottomley, A; EORTC PROBE The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative.
J Natl Cancer Inst. 2016; 108(5): [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Hofmann, NA; Yang, J; Trauger, SA; Nakayama, H; Huang, L; Strunk, D; Moses, MA; Klagsbrun, M; Bischoff, J; Graier, WF The GPR 55 agonist, L-α-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis.
Br J Pharmacol. 2015; 172(16):4107-4118 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Marth, C; Hubalek, M; Petru, E; Polterauer, S; Reinthaller, A; Schauer, C; Scholl-Firon, T; Singer, CF; Zschocke, J; Zeimet, AG AGO Austria recommendations for genetic testing of patients with ovarian cancer.
Wien Klin Wochenschr. 2015; 127(15-16):652-654 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Singer, CF; Tea, MK; Pristauz, G; Hubalek, M; Rappaport, C; Riedl, CC; Helbich, TH Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families.
Wien Klin Wochenschr. 2015; 127(23-24):981-986
Web of Science PubMed FullText FullText_MUG

 

2014

Paradowski, J; Tomaszewski, KA; Bereza, K; Tomaszewska, IM; Pasternak, A; Paradowska, D; Szczęsny, E; Golec, EB; Greimel, ER; Bottomley, A Validation of the Polish version of the EORTC QLQ-OV28 module for the assessment of health-related quality of life in women with ovarian cancer.
Expert Rev Pharmacoecon Outcomes Res. 2014; 14(1):157-163
Web of Science PubMed FullText FullText_MUG

 

Quinten, C; Martinelli, F; Coens, C; Sprangers, MA; Ringash, J; Gotay, C; Bjordal, K; Greimel, E; Reeve, BB; Maringwa, J; Ediebah, DE; Zikos, E; King, MT; Osoba, D; Taphoorn, MJ; Flechtner, H; Schmucker-Von Koch, J; Weis, J; Bottomley, A; Patient Reported Outcomes and Behavioral Evidence (PROBE) and the European Organization for Research and Treatment of Cancer (EORTC) Clinical Groups A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites.
Cancer. 2014; 120(2):302-311 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Smolle, E; Taucher, V; Haybaeck, J Malignant ascites in ovarian cancer and the role of targeted therapeutics.
Anticancer Res. 2014; 34(4):1553-1561
Web of Science PubMed

 

Smolle, E; Taucher, V; Petru, E; Haybaeck, J Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Anticancer Res. 2014; 34(4):1519-1530
Web of Science PubMed

 

2013

Dieplinger, B; Egger, M; Gabriel, C; Poelz, W; Morandell, E; Seeber, B; Kronenberg, F; Haltmayer, M; Mueller, T; Dieplinger, H Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma.
Clin Chim Acta. 2013; 425(11): 236-241. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Greimel, E; Kristensen, GB; van der Burg, ME; Coronado, P; Rustin, G; del Rio, AS; Reed, NS; Nordal, RR; Coens, C; Vergote, I; European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
Gynecol Oncol. 2013; 131(2):437-444
Web of Science PubMed FullText FullText_MUG

 

Smolle, E; Taucher, V; Pichler, M; Petru, E; Lax, S; Haybaeck, J Targeting signaling pathways in epithelial ovarian cancer.
Int J Mol Sci. 2013; 14(5):9536-9555 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Szkandera, J; Kiesslich, T; Haybaeck, J; Gerger, A; Pichler, M Hedgehog signaling pathway in ovarian cancer.
Int J Mol Sci. 2013; 14(1):1179-1196 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2012

Schulz, E; Valentin, A; Ulz, P; Beham-Schmid, C; Lind, K; Rupp, V; Lackner, H; Wölfler, A; Zebisch, A; Olipitz, W; Geigl, J; Berghold, A; Speicher, MR; Sill, H Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
J Med Genet. 2012; 49(7):422-428
Web of Science PubMed FullText FullText_MUG

 

Singer, CF; Tea, MK; Pristauz, G; Hubalek, M; Rappaport, C; Riedl, C; Helbich, T Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families
Wien Klin Wochenschr. 2012; 124(9-10):334-339
Web of Science PubMed FullText FullText_MUG

 

2011

Greimel, E; Daghofer, F; Petru, E Prospective assessment of quality of life in long-term ovarian cancer survivors.
Int J Cancer. 2011; 128(12): 3005-3011. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Greimel, ER; Bjelic-Radisic, V; Pfisterer, J; Hilpert, F; Daghofer, F; Pujade-Lauraine, E; du Bois, A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR); Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO) Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials.
Support Care Cancer. 2011; 19(9):1421-1427
Web of Science PubMed FullText FullText_MUG

 

Harter, P; Sehouli, J; Reuss, A; Hasenburg, A; Scambia, G; Cibula, D; Mahner, S; Vergote, I; Reinthaller, A; Burges, A; Hanker, L; Pölcher, M; Kurzeder, C; Canzler, U; Petry, KU; Obermair, A; Petru, E; Schmalfeldt, B; Lorusso, D; du Bois, A Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
Int J Gynecol Cancer. 2011; 21(2):289-295 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Kurtz, JE; Kaminsky, MC; Floquet, A; Veillard, AS; Kimmig, R; Dorum, A; Elit, L; Buck, M; Petru, E; Reed, N; Scambia, G; Varsellona, N; Brown, C; Pujade-Lauraine, E; on behalf of Gynecologic Cancer Intergroup Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
ANN ONCOL. 2011; 22(11): 2417-2423. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Lee, CK; Gurney, H; Brown, C; Sorio, R; Donadello, N; Tulunay, G; Meier, W; Bacon, M; Maenpaa, J; Petru, E; Reed, N; Gebski, V; Pujade-Lauraine, E; Lord, S; Simes, RJ; Friedlander, M Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
BRIT J CANCER. 2011; 105(3): 360-365. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Watzka, SB; Posch, F; Pass, HI; Huflejt, M; Bernhard, D; Hannigan, GE; Müller, MR Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.
J Thorac Cardiovasc Surg. 2011; 142(2):384-389 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2010

Greimel, E; Nordin, AJ Application of quality-of-life measurements in clinical trials and in clinical practice for gynecologic cancer patients.
Expert Rev Pharmacoecon Outcomes Res. 2010; 10(1): 63-71.
Web of Science PubMed FullText FullText_MUG

 

Petru, E; Reinthaller, A; Angleitner-Boubenizek, L; Schauer, C; Zeimet, A; Dirschlmayer, W; Medl, M; Stummvoll, W; Sevelda, P; Marth, C Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.
WIEN KLIN WOCHENSCHR. 2010; 122(21-22): 649-652.
Web of Science PubMed FullText FullText_MUG

 

Pristauz, G; Geigl, JB; Petru, E BRCA1- and BRCA2 mutations: Clinical management of patients with hereditary breast and ovarian cancer.
Wien Med Wochenschr. 2010; 160(7-8): 158-162.
PubMed FullText FullText_MUG

 

Soriţău, O; Tomuleasa, CI; Páll, E; Virág, P; Fischer-Fodor, E; Foris, V; Barbos, O; Tatomir, C; Kacsó, G; Irimie, A Enhanced chemoresistance and tumor sphere formation as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancer.
Rom J Morphol Embryol. 2010; 51(2):259-264 [OPEN ACCESS]
Web of Science PubMed

 

2009

Auner, V; Kriegshäuser, G; Tong, D; Horvat, R; Reinthaller, A; Mustea, A; Zeillinger, R KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
BMC Cancer. 2009; 9(1): 111-111. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Marth, C; Hiebl, S; Oberaigner, W; Winter, R; Leodolter, S; Sevelda, P Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology.
Int J Gynecol Cancer. 2009; 19(1):94-102
Web of Science PubMed FullText FullText_MUG

 

Petru, E; Luck, HJ; Stuart, G; Gaffney, D; Millan, D; Vergote, I Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system.
EUR J OBSTET GYN REPROD BIOL. 2009; 143(2): 69-74.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Reim, F; Dombrowski, Y; Ritter, C; Buttmann, M; Hausler, S; Ossadnik, M; Krockenberger, M; Beier, D; Beier, CP; Dietl, J; Becker, JC; Honig, A; Wischhusen, J Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Cancer Res. 2009; 69(20):8058-8066 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Zeimet, AG; Reimer, D; Radl, AC; Reinthaller, A; Schauer, C; Petru, E; Concin, N; Braun, S; Marth, C Pros and Cons of Intraperitoneal Chemotherapy in the Treatment of Epithelial Ovarian Cancer
ANTICANCER RES. 2009; 29(7): 2803-2808. [Keynote lecture]
Web of Science Google Scholar

 

Weitere 50 Treffer anzeigen
© Med Uni Graz Impressum